Non-hemodynamic effects of organic nitrates and the distinctive characteristics of pentaerithrityl tetranitrate

American Journal of Cardiovascular Drugs

Volumn 9, Issue 1, 2009, Pages 7-15

  Tommaso, Gori ^a,b,c   Daiber, Andreas ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTIOXIDANT; GLYCERYL TRINITRATE; ISOSORBIDE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; ORGANIC NITRATE; PENTAERYTHRITYL TETRANITRATE; REACTIVE OXYGEN METABOLITE;

AEROSOL; ANGINA PECTORIS; ARTERY DISEASE; AUTONOMIC DYSFUNCTION; BIOTRANSFORMATION; CELL PROTECTION; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DRUG STRUCTURE; DRUG TOLERANCE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; HEART FAILURE; HEMODYNAMICS; HUMAN; ISCHEMIA; ISCHEMIC PRECONDITIONING; LONG TERM CARE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STEM CELL; TABLET; VASODILATATION;

ANIMALS; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; HEART DISEASES; HUMANS; ISOSORBIDE DINITRATE; NITRATES; NITROGLYCERIN; OXIDATIVE STRESS; PENTAERYTHRITOL TETRANITRATE; REACTIVE OXYGEN SPECIES; VASODILATOR AGENTS;

EID: 59349090968     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200909010-00002     Document Type: Review

References (89)

1. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008; 7: 156-67
2. Kleschyov AL, Oelze M, Daiber A, et al. Does nitric oxide mediate the vasodilator activity of nitroglycerin? Circ Res 2003; 93: e104-12
3. Nunez C, Victor VM, Tur R, et al. Discrepancies between nitroglycerin and NO-releasing drugs on mitochondrial oxygen consumption, vasoactivity, and the release of NO. Circ Res 2005; 97: 1063-9
4. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 2005; 97: 618-28
5. Gori T, Parker JD. Nitrate tolerance: a unifying hypothesis. Circulation 2002; 106: 2510-3
6. Gori T, Parker JD. The puzzle of nitrate tolerance: pieces smaller than we thought? Circulation 2002; 106: 2404-8
7. Gori T, Parker JD. Nitrate-induced toxicity and preconditioning: a rationale for reconsidering the use of these drugs. J Am Coll Cardiol 2008; 52: 251-4
8. Gori T, Di Stolfo G, Dragoni S, et al. The mechanism of nitrate-induced preconditioning. Clin Hemorheol Microcirc 2008; 39: 191-6
9. Gori T, Floras JS, Parker JD. Nitroglycerin blunts the gain of the baroreceptor-heart rate reflex. Circulation 2001; 104: II-331
10. Gori T, Mak SS, Kelly S, et al. Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J Am Coll Cardiol 2001; 38: 1096-101
11. Death AK, Nakhla S, McGrath KC, et al. Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages. J Am Coll Cardiol 2002; 39: 1943-50
12. Heitzer T, Just H, Brockhoff C, et al. Long-term nitroglycerin treatment is associated with supersensitivity to vasoconstrictors in men with stable coronary artery disease: prevention by concomitant treatment with captopril. J Am Coll Cardiol 1998; 31: 83-8
13. Parker JD. Potential problems with intermittent nitrate therapy. Can J Cardiol 1996; 12 Suppl. C: 22C-4C
14. Nakamura Y, Moss AJ, Brown MW, et al. Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies. Multicenter Myocardial Ischemia Research Group. Am Heart J 1999; 138: 557-85
15. Ishikawa K, Kanamasa K, Ogawa I, et al. Long-term nitrate treatment increases cardiac events in patients with healed myocardial infarction. Secondary Prevention Group. Jpn Circ J 1996; 60: 779-88
16. Daiber A, Wenzel P, Oelze M, et al. New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance. Clin Res Cardiol 2008 Jan; 97 (1): 12-20
17. Neurath GB, Dunger M. Blood levels of the metabolites of glyceryl trinitrate and pentaerythritol tetranitrate after administration of a two-step preparation. Arzneimittelforschung 1977; 27: 416-9
18. Seeling A, Lehmann J. NO-donors, part X [1]: investigations on the stability of pentaerythrityl tetranitrate (PETN) by HPLC-chemoluminescence-N- detection (CLND) versus UV-detection in HPLC. J Pharm Biomed Anal 2006; 40: 1131-6
19. Weber W, Michaelis K, Luckow V, et al. Pharmacokinetics and bioavailability of pentaerithrityl tetranitrate and two of its metabolites. Arzneimittelforschung 1995; 45: 781-4
20. Haustein KO, Winkler U, Loffler A, et al. Absorption and bioavailability of pentaerithrityl-tetranitrate (PETN, Dilcoran 80). Int J Clin Pharmacol Ther 1995; 33: 95-102
21. Sun JX, Piraino AJ, Morgan JM, et al. Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. J Clin Pharmacol 1995; 35: 390-7
22. Woodward AJ, Lewis PA, Rudman AR, et al. Determination of nitroglycerin and its dinitrate metabolites in human plasma by high-performance liquid chromatography with thermal energy analyzer detection. J Pharm Sci 1984; 73: 1838-40
23. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med 1998; 338: 520-31
24. Daiber A, Oelze M, Coldewey M, et al. Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates. Mol Pharmacol 2004; 66: 1372-82
25. Koenig A, Lange K, Konter J, et al. Potency and in vitro tolerance of organic nitrates: partially denitrated metabolites contribute to the tolerance-devoid activity of pentaerythrityl tetranitrate. J Cardiovasc Pharmacol 2007; 50: 68-74
26. Jurt U, Gori T, Ravandi A, et al. Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study. J Am Coll Cardiol 2001; 38: 854-9
27. Fung HL, Chong S, Kowaluk E, et al. Mechanisms for the pharmacologic interaction of organic nitrates with thiols. Existence of an extracellular pathway for the reversal of nitrate vascular tolerance by N-acetylcysteine. J Pharmacol Exp Ther 1988; 245: 524-30
28. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A 2002; 99: 8306-11
29. Wenzel P, Hink U, Oelze M, et al. Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications formitochondrial oxidative stress and nitrate tolerance. J Biol Chem 2007; 282: 792-9
30. Chen Z, Stamler JS. Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Trends Cardiovasc Med 2006; 16: 259-65
31. Needleman P, Johnson Jr EM. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 1973; 184: 709-15
32. Wenzel P, Hink U, Oelze M, et al. Number of nitrate groups determines reactivity and potency of organic nitrates: a proof of concept study in ALDH-2-/- mice. Br J Pharmacol 2007; 150: 526-33
33. Munzel T, Sayegh H, Freeman BA, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995; 95: 187-94
34. Daiber A, Oelze M, Sulyok S, et al. Heterozygous deficiency of manganese superoxide dismutase in mice (Mn-SOD+/-) as a novel approach to assess the role of oxidative stress for the development of nitrate tolerance. Mol Pharmacol 2005 Sep; 68 (3): 579-88
35. Schulz E, Tsilimingas N, Rinze R, et al. Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 2002; 105: 1170-5
36. Abou-Mohamed G, Kaesemeyer WH, Caldwell RB, et al. Role of L-arginine in the vascular actions and development of tolerance to nitroglycerin. Br J Pharmacol 2000; 130: 211-8
37. Mihm MJ, Coyle CM, Jing L, et al. Vascular peroxynitrite formation during organic nitrate tolerance. J Pharmacol Exp Ther 1999; 291: 194-8
38. Hink U, Oelze M, Kolb P, et al. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol 2003; 42: 1826-34
39. Gori T, Saunders L, Ahmed S, et al. Effect of folic acid on nitrate tolerance in healthy volunteers: differences between arterial and venous circulation. J Cardiovasc Pharmacol 2003; 41: 185-90
40. Sekiya M, Sato M, Funada J, et al. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 2005; 46: 63-7
41. Thomas GR, DiFabio JM, Gori T, et al. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol 2007; 49: 1289-95
42. Kurz S, Hink U, Nickenig G, et al. Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation 1999; 99: 3181-7
43. Munzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 1996; 98: 1465-70
44. Szocs K, Lassegue B, Wenzel P, et al. Increased superoxide production in nitrate tolerance is associated with NAD(P)H oxidase and aldehyde dehydrogenase 2 downregulation. J Mol Cell Cardiol 2007; 42: 1111-8
45. Sydow K, Daiber A, Oelze M, et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 2004; 113: 482-9
46. Sage PR, de la Lande I, Stafford I, et al. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation 2000; 102: 2810-5
47. Munzel T, Hink U, Yigit H, et al. Role of superoxide dismutase in in vivo and in vitro nitrate tolerance. Br J Pharmacol 1999; 127: 1224-30
48. Ahlner J, Andersson RG, Torfgard K, et al. Organic nitrate esters: clinical use and mechanisms of actions. Pharmacol Rev 1991; 43: 351-423
49. Mullenheim J, Muller S, Laber U, et al. The effect of high-dose pentaerythritol tetranitrate on the development of nitrate tolerance in rabbits. Naunyn Schmiedebergs Arch Pharmacol 2001; 364: 269-75
50. Fink B, Bassenge E. Unexpected, tolerance-devoid vasomotor and platelet actions of pentaerythrityl tetranitrate. J Cardiovasc Pharmacol 1997; 30: 831-6
51. Mollnau H, Wenzel P, Oelze M, et al. Mitochondrial oxidative stress and nitrate tolerance - comparison of nitroglycerin and pentaerithrityl tetranitrate in Mn-SOD+/- mice. BMC Cardiovasc Disord 2006; 6: 44
52. Wenzel P, Oelze M, Coldewey M, et al. Heme oxygenase-1: a novel key player in the development of tolerance in response to organic nitrates. Arterioscler Thromb Vasc Biol 2007; 27: 1729-35
53. Kojda G, Stein D, Kottenberg E, et al. In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits. J Cardiovasc Pharmacol 1995; 25: 763-73
54. Kojda G, Hacker A, Noack E. Effects of nonintermittent treatment of rabbits with pentaerythritol tetranitrate on vascular reactivity and superoxide production. Eur J Pharmacol 1998; 355: 23-31
55. Oberle S, Schwartz P, Abate A, et al. The antioxidant defense protein ferritin is a novel and specific target for pentaerithrityl tetranitrate in endothelial cells. Biochem Biophys Res Commun 1999; 261: 28-34
56. Oberle S, Abate A, Grosser N, et al. Heme oxygenase-1 induction may explain the antioxidant profile of pentaerythrityl trinitrate. Biochem Biophys Res Commun 2002; 290: 1539-44
57. Dragoni S, Gori T, Lisi M, et al. Pentaerythrityl tetranitrate and nitroglycerin, but not isosorbide mononitrate, prevent endothelial dysfunction induced by ischemia and reperfusion. Arterioscler Thromb Vasc Biol 2007; 27: 1955-9
58. Minetti M, Mallozzi C, Di Stasi AM, et al. Bilirubin is an effective antioxidant of peroxynitrite-mediated protein oxidation in human blood plasma. Arch Biochem Biophys 1998; 352: 165-74
59. Gori T, Harvey P, Floras JS, et al. Continuous therapy with nitroglycerin impairs endothelium-dependent vasodilation but does not cause tolerance in conductance arteries: a human in vivo study. J Cardiovasc Pharmacol 2004; 44: 601-6
60. Munzel T, Li H, Mollnau H, et al. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res 2000; 86: E7-12
61. Gori T, Daiber A, Di Stolfo G, et al. Nitroglycerine causes mitochondrial reactive oxygen species production: in vitro mechanistic insights. Can J Cardiol 2007; 23: 990-2
62. DiFabio JM, Thomas GR, Zucco L, et al. Nitroglycerin attenuates human endothelial progenitor cell differentiation, function, and survival. J Pharmacol Exp Ther 2006; 318: 117-23
63. Parker JD, Farrell B, Fenton T, et al. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991; 84: 2336-45
64. Parker JD. Counterregulatory responses: sustained-release isosorbide-5-mononitrate versus transdermal nitroglycerin. J Cardiovasc Pharmacol 1996; 28: 631-8
65. Caramori PR, Adelman AG, Azevedo ER, et al. Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine. J Am Coll Cardiol 1998; 32: 1969-74
66. Munzel T, Mollnau H, Hartmann M, et al. Effects of a nitrate-free interval on tolerance, vasoconstrictor sensitivity and vascular superoxide production. J Am Coll Cardiol 2000; 36: 628-34
67. Azevedo ER, Schofield AM, Kelly S, et al. Nitroglycerinwithdrawal increases endothelium-dependent vasomotor response to acetylcholine. J Am Coll Cardiol 2001; 37: 505-9
68. Dupuis J, Lalonde G, Lemieux R, et al. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990; 16: 923-31
69. Heitzer T, Baldus S, von Kodolitsch Y, et al. Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure. Arterioscler Thromb Vasc Biol 2005; 25: 1174-9
70. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36
71. Laghi PF, Capecchi PL, Acciavatti A, et al. Pharmacological preconditioning of ischaemia. Clin Hemorheol Microcirc 1997; 17: 73-84
72. Yada T, Shimokawa H, Kajiya F. Cardioprotective effect of hydroxyfasudil as a specific Rho-kinase inhibitor, on ischemia-reperfusion injury in canine coronary microvessels in vivo. Clin Hemorheol Microcirc 2006; 34: 177-83
73. Rezkalla SH, Kloner RA. Preconditioning in humans. Heart Fail Rev 2007; 12: 201-6
74. Leesar MA, Stoddard MF, Dawn B, et al. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation 2001; 103: 2935-41
75. Crisafulli A, Melis F, Tocco F, et al. Exercise-induced and nitroglycerin-induced myocardial preconditioning improves hemodynamics in patients with angina. Am J Physiol Heart Circ Physiol 2004; 287: H235-42
76. Daiber A, Oelze M, August M, et al. Detection of superoxide and peroxynitrite in model systems and mitochondria by the luminol analogue L-012. Free Radic Res 2004; 38: 259-69
77. Lebuffe G, Schumacker PT, Shao ZH, et al. ROS and NO trigger early preconditioning: relationship to mitochondrial KATP channel. Am J Physiol Heart Circ Physiol 2003; 284: H299-308
78. Hausenloy D, Wynne A, Duchen M, et al. Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. Circulation 2004; 109: 1714-7
79. Gori T, Forconi S. The role of reactive free radicals in ischemic preconditioning - clinical and evolutionary implications. Clin Hemorheol Microcirc 2005; 33: 19-28
80. Gori T, Fineschi M, Parker JD, et al. Current perspectives. Therapy with organic nitrates: newer ideas, more controversies. Ital Heart J 2005; 6: 541-8
81. Gladwin MT, Schechter AN, Kim-Shapiro DB, et al. The emerging biology of the nitrite anion. Nat Chem Biol 2005; 1: 308-14
82. Bryan NS, Calvert JW, Elrod JW, et al. Dietary nitrite supplementation protects against myocardial ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2007; 104: 19144-9
83. Dezfulian C, Raat N, Shiva S, et al. Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics. Cardiovasc Res 2007; 75: 327-38
84. Thum T, Fraccarollo D, Thum S, et al. Differential effects of organic nitrates on endothelial progenitor cells are determined by oxidative stress. Arterioscler Thromb Vasc Biol 2007; 27: 748-54
85. Richartz BM, Schneider HT, Silber S. PETN: long acting nitrate with tolerance devoiding properties and innovative potential [in German]. MMW Fortschr Med 2008; 150 Suppl. 1: 43-7
86. Munzel T. Special place of PETN among nitrates. No tolerance development, fewer headaches [in German]. MMW Fortschr Med 2008; 150: 41
87. Gori T, Al Hesayen A, Jolliffe C, et al. Comparison of the effects of pentaerythritol tetranitrate and nitroglycerin on endothelium-dependent vasorelaxation in male volunteers. Am J Cardiol 2003; 91: 1392-4
88. Jancso G, Cserepes B, Gasz B, et al. Expression and protective role of heme oxygenase-1 in delayed myocardial preconditioning. Ann N Y Acad Sci 2007; 1095: 251-61
89. Berenshtein E, Vaisman B, Goldberg-Langerman C, et al. Roles of ferritin and iron in ischemic preconditioning of the heart. Mol Cell Biochem 2002; 234-235: 283-92